Astrana Health Inc (ASTH)vsDaVita HealthCare Partners Inc (DVA)
ASTH
Astrana Health Inc
$37.99
+0.37%
HEALTHCARE · Cap: $1.87B
DVA
DaVita HealthCare Partners Inc
$192.16
-0.01%
HEALTHCARE · Cap: $13.39B
Smart Verdict
WallStSmart Research — data-driven comparison
DaVita HealthCare Partners Inc generates 292% more annual revenue ($13.84B vs $3.53B). DVA leads profitability with a 5.7% profit margin vs 0.9%. DVA trades at a lower P/E of 20.1x. DVA earns a higher WallStSmart Score of 70/100 (B-).
ASTH
Buy56
out of 100
Grade: C
DVA
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.9%
Fair Value
$188.57
Current Price
$37.99
$150.58 discount
Margin of Safety
-17.0%
Fair Value
$123.34
Current Price
$192.16
$68.82 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.6% year-over-year
Earnings expanding 110.1% YoY
Reasonable price relative to book value
Every $100 of equity generates 81 in profit
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 43.5% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of 3.8% — below average capital efficiency
0.9% margin — thin
Operating margin of 3.0%
5.7% margin — thin
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ASTH
The strongest argument for ASTH centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 55.6% demonstrates continued momentum.
Bull Case : DVA
The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.65 suggests the stock is reasonably priced for its growth.
Bear Case : ASTH
The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 61.7x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.
Bear Case : DVA
The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.
Key Dynamics to Monitor
ASTH profiles as a hypergrowth stock while DVA is a value play — different risk/reward profiles.
ASTH carries more volatility with a beta of 0.99 — expect wider price swings.
ASTH is growing revenue faster at 55.6% — sustainability is the question.
DVA generates stronger free cash flow (219M), providing more financial flexibility.
Bottom Line
DVA scores higher overall (70/100 vs 56/100). ASTH offers better value entry with a 89.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Astrana Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.
DaVita HealthCare Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?